In human studies of lung [ 30] and cervical cancers [ 31], encouraging evidence has emerged that [Cu]ATSM can act as a prognostic indicator for response to therapy.
In human studies of lung [ 34] and cervix cervical cancers [ 35], encouraging evidence has emerged that Cu-ATSM can act as a prognostic indicator for response to therapy.
In human studies of lung and cervix cancers, encouraging evidence is emerging that Cu-ATSM can act as a prognostic indicator for response to therapy.
For example, GWAs conducted by three independent groups from North America, Australia/Northern Europe, and Japan (Holmes et al. 2011) demonstrated that the IL28B gene is a strong indicator for response to standard treatment in patients with hepatitis C virus-1 (HCV-1) infection.
In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival.
Since a rapid decline in functional quality of life was associated with a good therapeutic outcome, future trials on an extended number of advanced RCC patients receiving IL-2-based immunotherapy in a prospectively controlled trial setting may confirm that validated quality-of-life analyses can serve as an early prognostic indicator for response, and potentially also for survival.
A further aim could be the investigation of prognostic indicators for treatment response.
The observed associations between PGx and outcomes in this study are encouraging as potential indicators for patient response.
Nevertheless the concept of negative symptoms in schizophrenia has attracted much attention, since negative symptoms have been identified as important indicators for treatment response and prognosis.
Since mutation and copy number variation information are also important indicators for drug response and available in CCLE and CGP studies, we further investigated whether a joint model by integrating these information could possibly improve drug response prediction.
